Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
| Autor: | Camila Bezerra Melo Figueirêdo, Joelma Rodrigues de Souza, Daniel Handerson Galindo Soares, Caio Cesar de Andrade Rodrigues Silva, Virginia Maria Barros de Lorena |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Pharmaceutical Sciences, Vol 50, Iss 3, Pp 445-455 (2014) |
| Druh dokumentu: | article |
| ISSN: | 2175-9790 1984-8250 |
| DOI: | 10.1590/S1984-82502014000300002 |
| Popis: | Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected clinical and economic outcomes of treatments. The results from clinical tests indicate the need for a better understanding of the critical mechanisms of action of this antibody, which may maximize its therapeutic efficacy. This therapy not only represents a viable option to treat most types of NHLs, especially when associated with conventional chemotherapy, but also offers cost-utility and cost-effectiveness advantages. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|